دورية أكاديمية
Development of a quantitative fluorescence lateral flow immunoassay (LFIA) prototype for point-of-need detection of anti-Müllerian hormone
| العنوان: | Development of a quantitative fluorescence lateral flow immunoassay (LFIA) prototype for point-of-need detection of anti-Müllerian hormone |
|---|---|
| المؤلفون: | Heather J. Goux, Binh V. Vu, Katherine Wasden, Kannan Alpadi, Ajay Kumar, Bhanu Kalra, Gopal Savjani, Kristen Brosamer, Katerina Kourentzi, Richard C. Willson |
| المصدر: | Practical Laboratory Medicine, Vol 35, Iss , Pp e00314- (2023) |
| بيانات النشر: | Elsevier, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Medicine (General) LCC:Chemistry |
| مصطلحات موضوعية: | Lateral flow assay, Europium reporters, Antibody, Fluorescence, Biomarker, Quantitative, Medicine (General), R5-920, Chemistry, QD1-999 |
| الوصف: | Objective: Anti-Müllerian Hormone (AMH) is a quantitative marker for ovarian reserve and is used to predict response during ovarian stimulation. Streamlining testing to the clinic or even to the physician's office would reduce inconvenience, turnaround time, patient stress and potentially also the total cost of testing, allowing for more frequent monitoring. In this paper, AMH is used as a model biomarker to describe the rational development and optimization of sensitive, quantitative, clinic-based rapid diagnostic tests. Design and Methods: We developed a one-step lateral-flow europium (III) chelate-based fluorescent immunoassay (LFIA) for the detection of AMH on a portable fluorescent reader, optimizing the capture/detection antibodies, running buffer, and reporter conjugates. Results: A panel of commercial calibrators was used to develop a standard curve to determine the analytical sensitivity (LOD = 0.41 ng/ml) and the analytical range (0.41–15.6 ng/ml) of the LFIA. Commercial controls were then tested to perform an initial evaluation of the prototype performance and showed a high degree of precision (Control I CV 2.18%; Control II CV 3.61%) and accuracy (Control I recovery 126%; Control II recovery 103%). Conclusions: This initial evaluation suggests that, in future clinical testing, the AMH LFIA will likely have the capability of distinguishing women with low ovarian reserve (6 ng/ml). |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2352-5517 |
| Relation: | http://www.sciencedirect.com/science/article/pii/S2352551723000082; https://doaj.org/toc/2352-5517 |
| DOI: | 10.1016/j.plabm.2023.e00314 |
| URL الوصول: | https://doaj.org/article/fe9176c27966484e9f1aa0483e6c8ba4 |
| رقم الأكسشن: | edsdoj.fe9176c27966484e9f1aa0483e6c8ba4 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 23525517 |
|---|---|
| DOI: | 10.1016/j.plabm.2023.e00314 |